The full data reinforces hopes that the drug could be a breakthrough COPD treatment and reach AstraZeneca's peak annual sales forecast of more than $5 billion.

UBS has told investors that the recent slide in AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares has gone too far, keeping its buy rating on the FTSE 100 drugmaker even after two clinical setbacks and speculation about a mega-merger.

SERENA-4 was assessing AstraZeneca’s Etcamah as a first-line option for certain patients with advanced breast cancer—a setting that could have meant a $2.9 billion opportunity for the drug.

An experimental COPD drug from AstraZeneca could prove competitive with existing treatments, and have a slice of the market to itself.

On September 5, 2026, Bloomberg reported that the FDA granted accelerated approval to AstraZeneca PLC (NYSE:AZN)’s camizestrant, sold as Etcamah, for a genetically driven form of metastatic breast cancer.

A committee said the volrustomig combination was unlikely to reach either of the primary endpoints for the trial, but the company said other Phase 3 volrustomig trials would continue as planned.

AstraZeneca (AZN) stock gains 0.63% after CEO purchases £7.26M in shares and EU recommends Klygefa approval for rare autoimmune disorder treatment.

AstraZeneca's breast cancer pill was authorized in an accelerated approval process, following an earlier vote against the medicine by the FDA's advisory panel.

AstraZeneca (AZN) stock edges up 0.63% as CEO buys 60,000 shares and the EU recommends Klygefa for myasthenia gravis treatment.

AstraZeneca (LSE:AZN) and Daiichi Sankyo reported DESTINY-Lung04 Phase III results showing ENHERTU delayed disease progression in HER2-mutant advanced NSCLC versus standard therapy. Long-term follow-up data for TAGRISSO indicated eight-year survival benefits in early-stage EGFR-mutated lung cancer patients already on treatment protocols.